Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Assessment (2023) Covering Clinical Trials, Emerging Therapies, FDA, EMA, and PMDA Approvals | Fulcrum Therapeutics, Dyne Therapeutics, Hoffmann-La Roche, aTyr Pharma, Avidity Biosciences

Las Vega (Nevada), United States //- As per DelveInsight's assessment, globally, about 10+ key pharma and biotech companies are working on 10+ pipeline drugs in the Facioscapulohumeral Muscular Dystrophy (FSHD) therapeutics landscape based on different Routes of Administration (ROA), Mechanism of Action (MOA), and molecule types. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.

"Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Insight, 2023" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Facioscapulohumeral Muscular Dystrophy Therapeutics Market.

The report provides a detailed description of the Facioscapulohumeral Muscular Dystrophy drugs, including the mechanism of action, type, stage, route of administration, molecule type, clinical studies, inactive pipeline products, and NDA approvals (if any). The report also covers commercial and clinical activities of the pipeline products from the pre-clinical developmental phase to the marketed stage. Additionally, it presents the ongoing developments in the therapeutics segment, including collaborations, licensing, mergers & acquisitions (M&A), funding, designations, and other product-related details.

Get a Detailed Overview of the Facioscapulohumeral Muscular Dystrophy Clinical Trial Activities and Regulatory Developments in the domain:
https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Facioscapulohumeral Muscular Dystrophy (FSHD) Pipeline Analysis
The report provides insights into:
• The report provides detailed insights into the key companies that are developing Facioscapulohumeral Muscular Dystrophy therapies.
• The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Facioscapulohumeral Muscular Dystrophy treatment.
• It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• It navigates the emerging Facioscapulohumeral Muscular Dystrophy drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement in the Facioscapulohumeral Muscular Dystrophy treatment market.

Learn More about the Clinical and Commercial Development Activities in the Facioscapulohumeral Muscular Dystrophy Therapeutics Domain:
https://www.delveinsight.com/report-store/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

The Report Covers the Emerging Facioscapulohumeral Muscular Dystrophy Therapies Under Different Phases of Clinical Development Like -
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Route of Administration
Facioscapulohumeral Muscular Dystrophy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Intra-articular
• Intraocular
• Intrathecal
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

Molecule Type
Products have been categorized under various Molecule types such as
• Oligonucleotide
• Peptide
• Small molecule

Request for Sample PDF to Understand More About the Facioscapulohumeral Muscular Dystrophy Treatment Outlook and Future Perspectives:
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Facioscapulohumeral Muscular Dystrophy (FSHD) Therapeutics Analysis
There are currently no disease-modifying treatments for FSHD; supportive care is the mainstay of managing FSHD. This care primarily occurs in the context of physical therapy and rehabilitation exercises. Managing pain and fatigue in FSHD patients is essential, as both symptoms can affect patient psychology. Chronic pain is manageable with analgesic and antidepressant therapy to improve the quality of life in FSHD patients

Several major pharma and biotech companies are developing therapies for Facioscapulohumeral Muscular Dystrophy. Several of the therapies are in the advanced stages of clinical development and are expected to hit the market in the near future.

Facioscapulohumeral Muscular Dystrophy (FSHD) Companies in the Therapeutics Market Include:
• Fulcrum Therapeutics
• Dyne Therapeutics.
• Hoffmann-La Roche
• aTyr Pharma, Inc.
• Avidity Biosciences, Inc.
And Many Others

Emerging and Marketed Facioscapulohumeral Muscular Dystrophy (FSHD) Therapies Covered in the Report Include:
• Losmapimod: Fulcrum Therapeutics
• DYNE-301: Dyne Therapeutics
• AOC 1020: Avidity Biosciences
• MC-DX4: miRecule
• Losmapimod: Fulcrum Therapeutics
And Many More

Get an in-depth Assessment of the Emerging Therapies and Facioscapulohumeral Muscular Dystrophy Companies Actively Working in the Market:
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

Table of Content
1. Report Introduction
2. Executive Summary
3. Facioscapulohumeral Muscular Dystrophy Current Treatment Patterns
4. Facioscapulohumeral Muscular Dystrophy - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Facioscapulohumeral Muscular Dystrophy Late-Stage Products (Phase-III)
7. Facioscapulohumeral Muscular Dystrophy Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Facioscapulohumeral Muscular Dystrophy Discontinued Products
13. Facioscapulohumeral Muscular Dystrophy Product Profiles
14. Facioscapulohumeral Muscular Dystrophy Companies
15. Facioscapulohumeral Muscular Dystrophy Drugs
16. Dormant and Discontinued Products
17. Facioscapulohumeral Muscular Dystrophy Unmet Needs
18. Facioscapulohumeral Muscular Dystrophy Future Perspectives
19. Facioscapulohumeral Muscular Dystrophy Analyst Review
20. Appendix
21. Report Methodology

Get Detailed Insights About the Reports Offerings:
https://www.delveinsight.com/sample-request/facioscapulohumeral-muscular-dystrophy-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=rpr

-------------------------------------------- xx --------------------------------------------
Other Trending Healthcare Reports by DelveInsight -
Atopic Dermatitis Market
https://www.delveinsight.com/report-store/atopic-dermatitis-market

Concussions Market
https://www.delveinsight.com/report-store/concussions-market

Human Immunodeficiency Virus Type-1 (HIV-1) Market
https://www.delveinsight.com/report-store/human-immunodeficiency-virus-type-1-hiv-1-market

Hot Flashes Market
https://www.delveinsight.com/report-store/hot-flashes-market

Throat Cancer Market
https://www.delveinsight.com/report-store/throat-cancer-market

Traumatic Brain Injury Market
https://www.delveinsight.com/report-store/traumatic-brain-injury-market

Acute lymphocytic leukemia (ALL) Market
https://www.delveinsight.com/report-store/acute-lymphocytic-leukemia-all-market

Autism Spectrum Disorder Market
https://www.delveinsight.com/report-store/autism-spectrum-disorder-asd-market

Preeclampsia Market
https://www.delveinsight.com/report-store/preeclampsia-market

Spirometers Market
https://www.delveinsight.com/report-store/spirometers-market

Trastuzumab Biosimilars
https://www.delveinsight.com/report-store/trastuzumab-biosimilars-insight

Cushing's Syndrome Market
https://www.delveinsight.com/report-store/cushings-syndrome-market

Hemophilia A Market
https://www.delveinsight.com/report-store/hemophilia-a2030-market

Bone Resorption Market
https://www.delveinsight.com/report-store/bone-resorption-market

Erectile Dysfunction Market
https://www.delveinsight.com/report-store/erectile-dysfunction-market

Contact Info:
Shruti Thakur
Manager - Marketing & International Branding
Email: info@delveinsight.com

428, D21 Corporate Park, Sector-21, Dwarka, New Delhi-110077, India

About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

This release was published on openPR.